Daratumumab-Hyaluronidase-Fihj

Brand name: Darzalex Faspro

Rank #418 of 500 drugs by total cost

Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026

$21.0M

Total Cost

Share:

1,444

Total Claims

$21.0M

Total Cost

60

Prescribers

$15K

Cost per Claim

0

Beneficiaries

1,445

30-Day Fills

$349K

Avg Cost/Provider

24

Avg Claims/Provider

Share of Medicare Part D Spending

0.01%

of total Medicare Part D spending

$21.0M of $275.65B

Top Prescribers by Cost

Top 10 prescribers of $21.0M total

🔎 Data Overview

💰

At $14,513 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.

🔍

Average cost of $349,283 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Top Prescribers of Daratumumab-Hyaluronidase-Fihj

#ProviderSpecialtyLocationClaimsCost
1Debashish MisraHematology-OncologyCambridge, MA72$927K
2Alfredo Torres GonzalezHematology-OncologyPort Jefferson Station, NY52$759K
3James BerensonHematology-OncologyWest Hollywood, CA42$676K
4Ari BaronHematology-OncologySan Francisco, CA37$664K
5Norland NgHematology-OncologyNew York, NY19$664K
6Manish DhawanHematology-OncologyMinden, LA23$620K
7Deepali SharmaInternal MedicineRiverhead, NY34$610K
8Richard GordonHematology-OncologyVoorhees, NJ35$590K
9Myron BednarHematologyFlemington, NJ32$586K
10Youram NassirHematologyLos Angeles, CA16$572K
11Ramsey AsmarHematology-OncologyBrooklyn, NY23$555K
12Abhirami VivekanandarajahInternal MedicineStaten Island, NY37$534K
13Efat AziziMedical OncologyStaten Island, NY31$518K
14Steven MontanaHematology-OncologyEast Setauket, NY43$516K
15Sudhir HansaliaHematology-OncologyTrinity, FL51$496K

Top prescribers ranked by total cost for this drug in 2023.

Related Drugs by Cost

Related Analysis

Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology